" class="no-js "lang="en-US"> GeneQuantum Announces a Key Leadership Appointment - Pharmtech Focus
Thursday, January 26, 2023

GeneQuantum Announces a Key Leadership Appointment

GeneQuantum Healthcare, an industry leading biopharmacetucial company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced a key appointment to further strengthen GeneQuantum management team. Dr. Kaida Wu joins GQ as Chief Medical Officer, and will report to Dr. Gang Qin, Founder Chairman and CEO of GeneQuantum.

“We are delighted to welcome Dr. Wu to join our management team,” Dr. Gang Qin said, “GeneQuantum tries its best to accelerate the development of innovative bioconjugate drugs represented by Antibody-Drug-Conjugate (ADC) through our unique iLDC platform to provide more efficient, safer and more accessible innovative solutions for cancer patients worldwide. Dr. Wu’s joining GQ marks a concrete step forward in our strategic planning of establishing and expanding a world-class clinical team. His extensive expertise and excellent leadership capability are crucial for the success of the company. We do expect his contribution to the acceleration of our ADC drug development so that patients will benefit earlier from our effective product.”

Dr. Kaida Wu received his doctoral degree from Aarhus University in Denmark. Dr. Wu has nearly twenty year experience in biological pharmaceutical industry and more than ten years of hematologic tumor clinical practice, who has served in many famous institutions and multinational pharma including AstraZeneca, Sanofi, Janssen, Celgene, Bristol Myers Squibb, Memorial Sloan Kettering Cancer Center, and has successful proven track records in translational medicine research, clinical research, drug approval and marketing. Dr. Wu has outstanding ability in cutting-edge scientific knowledge integration, clinical trial design and clinical operations and has successfully achievements in clinical strategies and trial implement.

Dr. Wu expressed his great pleasure in joining GeneQuantum, he stated, “I am honored to join GeneQuantum. As a fast-growing global biopharmaceutical company, GeneQuantum owns advanced technology platform, strong ADC product pipelines, and industry leading talents and team members with master’s and Doctoral degrees from China or oversea.  I will work with GQ’s management team to accelerate the clinical development of product pipeline and bring more effective and safer new drugs to patients worldwide.”

People In This Post

Companies In This Post

  1. Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Read more
  2. Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Read more
  3. Sharecare Launches VR Program to Improve Well-being of American Workforce Read more
  4. Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Read more
  5. Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Read more